217 related articles for article (PubMed ID: 36401732)
1. The oral selective estrogen receptor degrader GDC-0810 (ARN-810) in postmenopausal women with hormone receptor-positive HER2-negative (HR + /HER2 -) advanced/metastatic breast cancer.
Bardia A; Mayer I; Winer E; Linden HM; Ma CX; Parker BA; Bellet M; Arteaga CL; Cheeti S; Gates M; Chang CW; Fredrickson J; Spoerke JM; Moore HM; Giltnane J; Friedman LS; Chow Maneval E; Chan I; Jhaveri K
Breast Cancer Res Treat; 2023 Jan; 197(2):319-331. PubMed ID: 36401732
[TBL] [Abstract][Full Text] [Related]
2. An Open-label Phase I Study of GDC-0927 in Postmenopausal Women with Locally Advanced or Metastatic Estrogen Receptor-Positive Breast Cancer.
Chandarlapaty S; Dickler MN; Perez Fidalgo JA; Villanueva-Vázquez R; Giltnane J; Gates M; Chang CW; Cheeti S; Fredrickson J; Wang X; Collier A; Moore HM; Metcalfe C; Lauchle J; Humke EW; Bardia A
Clin Cancer Res; 2023 Aug; 29(15):2781-2790. PubMed ID: 37261814
[TBL] [Abstract][Full Text] [Related]
3. Phase I Study of Elacestrant (RAD1901), a Novel Selective Estrogen Receptor Degrader, in ER-Positive, HER2-Negative Advanced Breast Cancer.
Bardia A; Kaklamani V; Wilks S; Weise A; Richards D; Harb W; Osborne C; Wesolowski R; Karuturi M; Conkling P; Bagley RG; Wang Y; Conlan MG; Kabos P
J Clin Oncol; 2021 Apr; 39(12):1360-1370. PubMed ID: 33513026
[TBL] [Abstract][Full Text] [Related]
4. AMEERA-1 phase 1/2 study of amcenestrant, SAR439859, in postmenopausal women with ER-positive/HER2-negative advanced breast cancer.
Bardia A; Chandarlapaty S; Linden HM; Ulaner GA; Gosselin A; Cartot-Cotton S; Cohen P; Doroumian S; Paux G; Celanovic M; Pelekanou V; Ming JE; Ternès N; Bouaboula M; Lee JS; Bauchet AL; Campone M
Nat Commun; 2022 Jul; 13(1):4116. PubMed ID: 35840573
[TBL] [Abstract][Full Text] [Related]
5. Phase 1 study of oral selective estrogen receptor degrader (SERD) amcenestrant (SAR439859), in Japanese women with ER-positive and HER2-negative advanced breast cancer (AMEERA-2).
Tamura K; Mukohara T; Yonemori K; Kawabata Y; Nicolas X; Tanaka T; Iwata H
Breast Cancer; 2023 May; 30(3):506-517. PubMed ID: 36977973
[TBL] [Abstract][Full Text] [Related]
6. Phase Ib Dose-escalation/Expansion Trial of Ribociclib in Combination With Everolimus and Exemestane in Postmenopausal Women with HR
Bardia A; Modi S; Oliveira M; Cortes J; Campone M; Ma B; Dirix L; Weise A; Hewes B; Diaz-Padilla I; Han Y; Deshpande P; Samant TS; Lorenc KR; He W; Su F; Chavez-MacGregor M
Clin Cancer Res; 2020 Dec; 26(24):6417-6428. PubMed ID: 32998962
[TBL] [Abstract][Full Text] [Related]
7. Open-label, phase II, multicenter study of lasofoxifene plus abemaciclib for treating women with metastatic ER+/HER2- breast cancer and an ESR1 mutation after disease progression on prior therapies: ELAINE 2.
Damodaran S; O'Sullivan CC; Elkhanany A; Anderson IC; Barve M; Blau S; Cherian MA; Peguero JA; Goetz MP; Plourde PV; Portman DJ; Moore HCF
Ann Oncol; 2023 Dec; 34(12):1131-1140. PubMed ID: 38072513
[TBL] [Abstract][Full Text] [Related]
8. Phase Ia/b Study of Giredestrant ± Palbociclib and ± Luteinizing Hormone-Releasing Hormone Agonists in Estrogen Receptor-Positive, HER2-Negative, Locally Advanced/Metastatic Breast Cancer.
Jhaveri KL; Bellet M; Turner NC; Loi S; Bardia A; Boni V; Sohn J; Neilan TG; Villanueva-Vázquez R; Kabos P; García-Estévez L; López-Miranda E; Pérez-Fidalgo JA; Pérez-García JM; Yu J; Fredrickson J; Moore HM; Chang CW; Bond JW; Eng-Wong J; Gates MR; Lim E
Clin Cancer Res; 2024 Feb; 30(4):754-766. PubMed ID: 37921755
[TBL] [Abstract][Full Text] [Related]
9. Elacestrant (oral selective estrogen receptor degrader) Versus Standard Endocrine Therapy for Estrogen Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Advanced Breast Cancer: Results From the Randomized Phase III EMERALD Trial.
Bidard FC; Kaklamani VG; Neven P; Streich G; Montero AJ; Forget F; Mouret-Reynier MA; Sohn JH; Taylor D; Harnden KK; Khong H; Kocsis J; Dalenc F; Dillon PM; Babu S; Waters S; Deleu I; García Sáenz JA; Bria E; Cazzaniga M; Lu J; Aftimos P; Cortés J; Liu S; Tonini G; Laurent D; Habboubi N; Conlan MG; Bardia A
J Clin Oncol; 2022 Oct; 40(28):3246-3256. PubMed ID: 35584336
[TBL] [Abstract][Full Text] [Related]
10. A First-in-Human Study of the New Oral Selective Estrogen Receptor Degrader AZD9496 for ER
Hamilton EP; Patel MR; Armstrong AC; Baird RD; Jhaveri K; Hoch M; Klinowska T; Lindemann JPO; Morgan SR; Schiavon G; Weir HM; Im SA
Clin Cancer Res; 2018 Aug; 24(15):3510-3518. PubMed ID: 29440181
[No Abstract] [Full Text] [Related]
11. A phase 1b study evaluating the effect of elacestrant treatment on estrogen receptor availability and estradiol binding to the estrogen receptor in metastatic breast cancer lesions using
Jager A; de Vries EGE; der Houven van Oordt CWM; Neven P; Venema CM; Glaudemans AWJM; Wang Y; Bagley RG; Conlan MG; Aftimos P
Breast Cancer Res; 2020 Sep; 22(1):97. PubMed ID: 32912274
[TBL] [Abstract][Full Text] [Related]
12. Modeling the novel SERD elacestrant in cultured fulvestrant-refractory HR-positive breast circulating tumor cells.
Dubash TD; Bardia A; Chirn B; Reeves BA; LiCausi JA; Burr R; Wittner BS; Rai S; Patel H; Bihani T; Arlt H; Bidard FC; Kaklamani VG; Aftimos P; Cortés J; Scartoni S; Fiascarelli A; Binaschi M; Habboubi N; Iafrate AJ; Toner M; Haber DA; Maheswaran S
Breast Cancer Res Treat; 2023 Aug; 201(1):43-56. PubMed ID: 37318638
[TBL] [Abstract][Full Text] [Related]
13. Lasofoxifene versus fulvestrant for ER+/HER2- metastatic breast cancer with an ESR1 mutation: results from the randomized, phase II ELAINE 1 trial.
Goetz MP; Bagegni NA; Batist G; Brufsky A; Cristofanilli MA; Damodaran S; Daniel BR; Fleming GF; Gradishar WJ; Graff SL; Grosse Perdekamp MT; Hamilton E; Lavasani S; Moreno-Aspitia A; O'Connor T; Pluard TJ; Rugo HS; Sammons SL; Schwartzberg LS; Stover DG; Vidal GA; Wang G; Warner E; Yerushalmi R; Plourde PV; Portman DJ; Gal-Yam EN
Ann Oncol; 2023 Dec; 34(12):1141-1151. PubMed ID: 38072514
[TBL] [Abstract][Full Text] [Related]
14. Clinical Efficacy and Whole-Exome Sequencing of Liquid Biopsies in a Phase IB/II Study of Bazedoxifene and Palbociclib in Advanced Hormone Receptor-Positive Breast Cancer.
Tsuji J; Li T; Grinshpun A; Coorens T; Russo D; Anderson L; Rees R; Nardone A; Patterson C; Lennon NJ; Cibulskis C; Leshchiner I; Tayob N; Tolaney SM; Tung N; McDonnell DP; Krop IE; Winer EP; Stewart C; Getz G; Jeselsohn R
Clin Cancer Res; 2022 Dec; 28(23):5066-5078. PubMed ID: 36215125
[TBL] [Abstract][Full Text] [Related]
15. Design of SERENA-6, a phase III switching trial of camizestrant in
Turner N; Huang-Bartlett C; Kalinsky K; Cristofanilli M; Bianchini G; Chia S; Iwata H; Janni W; Ma CX; Mayer EL; Park YH; Fox S; Liu X; McClain S; Bidard FC
Future Oncol; 2023 Mar; 19(8):559-573. PubMed ID: 37070653
[TBL] [Abstract][Full Text] [Related]
16. US Food and Drug Administration Approval Summary: Elacestrant for Estrogen Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative,
Shah M; Lingam H; Gao X; Gittleman H; Fiero MH; Krol D; Biel N; Ricks TK; Fu W; Hamed S; Li F; Sun JJ; Fan J; Schuck R; Grimstein M; Tang L; Kalavar S; Abukhdeir A; Pathak A; Ghosh S; Bulatao I; Tilley A; Pierce WF; Mixter BD; Tang S; Pazdur R; Kluetz P; Amiri-Kordestani L
J Clin Oncol; 2024 Apr; 42(10):1193-1201. PubMed ID: 38381994
[TBL] [Abstract][Full Text] [Related]
17. Phase II trial of neoadjuvant letrozole and lapatinib in Asian postmenopausal women with estrogen receptor (ER) and human epidermal growth factor receptor 2 (HER2)-positive breast cancer [Neo-ALL-IN]: Highlighting the TILs, ER expressional change after neoadjuvant treatment, and FES-PET as potential significant biomarkers.
Park JH; Kang MJ; Ahn JH; Kim JE; Jung KH; Gong G; Lee HJ; Son BH; Ahn SH; Kim HH; Shin HJ; Moon DH; Kim SB
Cancer Chemother Pharmacol; 2016 Oct; 78(4):685-95. PubMed ID: 27491481
[TBL] [Abstract][Full Text] [Related]
18. Randomised, open-label, multicentric phase III trial to evaluate the safety and efficacy of palbociclib in combination with endocrine therapy, guided by ESR1 mutation monitoring in oestrogen receptor-positive, HER2-negative metastatic breast cancer patients: study design of PADA-1.
Berger F; Marce M; Delaloge S; Hardy-Bessard AC; Bachelot T; Bièche I; Pradines A; De La Motte Rouge T; Canon JL; André F; Arnould L; Clatot F; Lemonnier J; Marques S; Bidard FC;
BMJ Open; 2022 Mar; 12(3):e055821. PubMed ID: 35241469
[TBL] [Abstract][Full Text] [Related]
19. A First-in-Human Phase 1 Study of a Novel Selective Androgen Receptor Modulator (SARM), RAD140, in ER+/HER2- Metastatic Breast Cancer.
LoRusso P; Hamilton E; Ma C; Vidula N; Bagley RG; Troy S; Annett M; Yu Z; Conlan MG; Weise A
Clin Breast Cancer; 2022 Jan; 22(1):67-77. PubMed ID: 34565686
[TBL] [Abstract][Full Text] [Related]
20. The cyclin-dependent kinase 4/6 inhibitor palbociclib in combination with letrozole versus letrozole alone as first-line treatment of oestrogen receptor-positive, HER2-negative, advanced breast cancer (PALOMA-1/TRIO-18): a randomised phase 2 study.
Finn RS; Crown JP; Lang I; Boer K; Bondarenko IM; Kulyk SO; Ettl J; Patel R; Pinter T; Schmidt M; Shparyk Y; Thummala AR; Voytko NL; Fowst C; Huang X; Kim ST; Randolph S; Slamon DJ
Lancet Oncol; 2015 Jan; 16(1):25-35. PubMed ID: 25524798
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
